Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases

Breast Cancer Research

Volumn 13, Issue 6, 2011, Pages

  Adamo, Barbara ^a,b,c   Deal, Allison M ^d   Burrows, Emily ^c   Geradts, Joseph ^e   Hamilton, Erika ^e   Blackwell, Kimberly L ^e   Livasy, Chad ^f   Fritchie, Karen ^g   Prat, Aleix ^a,c   Harrell, J C ^a,c   Ewend, Matthew G ^a,c   Carey, Lisa A ^a,c   Miller, C R ^a,c   Anders, Carey K ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d IL   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f CAROLINAS MEDICAL CENTER   (United States)

^g MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN S6; PROTEIN KINASE B; S6 KINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; BRAIN TUMOR; BREAST TUMOR; ENZYMOLOGY; GENE EXPRESSION PROFILING; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL;

ADULT; AGED; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 82355160843     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3071     Document Type: Article

References (42)

1. Kirsch D, Loeffler J. Brain metastases in patients with breast cancer: new horizons. Clin Breast Cancer 2005, 6:115-124. 10.3816/CBC.2005.n.013, 16001989.
2. Boogerd W, Vos V, Hart A, Baris G. Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol 1993, 15:165-174. 10.1007/BF01053937, 8509821.
3. Lin N, Bellon J, Winer E. CNS metastases in breast cancer. J Clin Oncol 2004, 22:3608-3617. 10.1200/JCO.2004.01.175, 15337811.
4. Gasper L. Recursive Partioning Analysis (RPA) of prognostic factors in three Radiation Oncology Treatment Group (RTOG) brain metastasis trials. Int J Radiat Oncol Biol Phys 1997, 37:745-751. 10.1016/S0360-3016(96)00619-0, 9128946.
5. Engel J. Determinants and prognosis of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 2003, 55:1186-1195. 10.1016/S0360-3016(02)04476-0, 12654426.
6. Isakoff S, Engelman J, Irie H, Luo J, Brachmann S, Pearline R, Cantley L, Brugge J. Breast cancer-associated PI3KA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005, 65:10992-11000. 10.1158/0008-5472.CAN-05-2612, 16322248.
7. Bunney T, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 2010, 10:342-352. 10.1038/nrc2842, 20414202.
8. Dillon R, White D, Muller W. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007, 26:1338-1345. 10.1038/sj.onc.1210202, 17322919.
9. Levine D, Bogomolniy F, Yee C, Lash A, Barakat R, Borgen P, Boyd J. Frequent mutation of the PI3KCA gene in ovarian and breast cancers. Hum Cancer Biol 2005, 11:2875-2878.
10. Li S, Rong M, Grieu F, Iacopetta B. PI3KCA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006, 96:91-95. 10.1007/s10549-005-9048-0, 16317585.
11. Tokunaga E, Kimura Y, Mashino K, Oki E, Kotaoka A, Ohno S, Morita M, Kakeji Y, Baba H, Maehara Y. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006, 13:137-144. 10.2325/jbcs.13.137, 16755107.
12. Vivanco I, Sawyers C. The phosphotidylinositol-3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501. 10.1038/nrc839, 12094235.
13. Sansal I, Sellers W. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004, 22:2954-2963. 10.1200/JCO.2004.02.141, 15254063.
14. Bose S, Chandran S, Mirocha J, Bose N. The AKT pathway in human breast cancer: a tissue-array-based analysis. Modern Pathol 2006, 19:238-245.
15. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091. 10.1158/0008-5472.CAN-07-6854, 2680495, 18676830.
16. Kesari S, Ramakrishna N, Sauvageot C, Stiles C, Wen P. Targeted molecular therapy of malignant gliomas. Curr Oncol Rep 2006, 8:58-70. 10.1007/s11912-006-0011-y, 16464405.
17. Mischel P, Cloughesy T. Targeted molecular therapy of GBM. Brain Pathol 2003, 13:52-61.
18. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med 2010, 2:43-55.
19. Harrell J, Prat A, Parker J, Fan C, He X, Carey L, Anders C, Ewend M, Perou C. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat 2011,
20. Zhang XHF, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massagué J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16:67-78. 10.1016/j.ccr.2009.05.017, 2749247, 19573813.
21. Anders CK, Deal AM, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA. The prognostic contribution of intrinsic breast cancer subtype, race, and age among patients with brain metastases. J Clin Oncol 2010, 28. abstr 1027.
22. Nam B-H, Kim SY, Han H-S, Kwon Y, Lee KS, Kim TH, Ro J. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008, 10:1-8.
23. Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 2010, 21:942-948. Epub 2009 Oct 19, 10.1093/annonc/mdp407, 19840953.
24. Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci USA 2009, 106:2835-2840. 10.1073/pnas.0813351106, 2636736, 19196980.
25. Engelman J. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562. 10.1038/nrc2664, 19629070.
26. Bader A, Kang S, Zhao L, Vogt P. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005, 5:921-929. 10.1038/nrc1753, 16341083.
27. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009, 15:5049-5059. 10.1158/1078-0432.CCR-09-0632, 19671852.
28. Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res 2008, 10:R27. 10.1186/bcr1984, 2397526, 18371219.
29. Brugge J, Hung M, Mills G. A new mutational aktivation in the PI3K pathway. Cancer Cell 2007, 12:104-107. 10.1016/j.ccr.2007.07.014, 17692802.
30. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R. PI3KCA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mututally exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65:2554-2559. 10.1158/0008-5472-CAN-04-3913, 15805248.
31. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency mutations of the PI3KCA gene in human cancers. Science 2004, 304:554. 10.1126/science.1096502, 15016963.
32. Aleskandarany M, Rakha E, Ahmed M, Powe D, Ellis I, Green A. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res Treat 2010,
33. Aleskandarany M, Rakha E, Ahmed M, Powe D, Paish E, Macmillan R, Ellis I, Green A. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat 2010, 122:45-53. 10.1007/s10549-009-0508-9, 19701705.
34. Akcakanat A, Sahin A, Shaye A, Velasco M, Meric-Bernstam F. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 2008, 112:2352-2358. 10.1002/cncr.23456, 2819051, 18386830.
35. Capodanno A, Camerini A, Orlandini C, Baldini E, Resta M, Bevilacqua G, Collecchi P. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum Pathol 2009, 40:1408-1417. 10.1016/j.humpath.2009.02.005, 19428048.
36. Fedele CG, Ooms LM, Ho M, Vieusseux J, O'Toole SA, Millar EK, Lopez-Knowles E, Sriratana A, Gurung R, Baglietto L, Giles GG, Bailey CG, Rasko JE, Shields BJ, Price JT, Majerus PW, Sutherland RL, Tiganis T, McLean CA, Mitchell CA. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci USA 2010, 107:22231-22236. 10.1073/pnas.1015245107, 3009830, 21127264.
37. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin WM, Rameh L, Salmena L, Pandolfi PP, Cantley LC. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009, 16:115-125. 10.1016/j.ccr.2009.06.006, 2957372, 19647222.
38. Pérez-Tenorio G, Alkhori L, Olsson B, Waltersson M, Nordenskjöld B, Rutqvist L, Skoog L, Stål O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007, 13:3577-3584. 10.1158/1078-0432.CCR-06-1609, 17575221.
39. Brogi E, Murray M, Nehhozina T, Akram M, Cranor M, Seidman A. Clinical and pathologic characteristics of brain metastases of breast carcinoma: a study of 74 patients. San Antonio Breast Cancer Symposium 2006, Abstract 4003.
40. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5:5-23. 10.1016/j.molonc.2010.11.003, 21147047.
41. Garcia-Echeverria C, Sellers W. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27:5511-5526. 10.1038/onc.2008.246, 18794885.
42. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 2011, 16(suppl 1):12-9.